Skip to content

PA · SAN.PA · DRUG MANUFACTURERS - GENERAL

Sanofi (SAN.PA) intrinsic value and stock valuation

$84.92as of 2026-11-21 · Mkt cap 91.01B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sanofi DCF and intrinsic value

InvestorsCraft values SAN.PA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SAN.PA’s statements →

Sanofi Graham Number

Graham Number: $92.00d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General Paris 75008 sanofi.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$43.6B+3.1% 5y CAGRd
20112025
Net income
$7.81B-8.7% 5y CAGRd
20112025
Free cash flow
$8.99B+11% 5y CAGRd
20112025
Total equity
$71.7B+2.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$43.6B$44.3B$41.1B$40.3B$39.2B
Operating income$14.3B$14.5B$13B$13.1B$8.13B
Net income$7.81B$5.56B$5.4B$8.37B$6.22B
EPSd$6.4M$4.44M$4.3M$6.69M$4.97M
Operating cash flow$10.8B$9.08B$10.3B$10.5B$10.5B
Capital expenditure-$-1.76B-$-3.2B-$-1.62B-$-2.2B-$-2.04B
Free cash flow$8.99B$5.89B$8.64B$8.33B$8.48B
Total assets$126.8B$132.8B$126.5B$126.7B$120.2B
Total debt$21.8B$17.9B$18.4B$21.2B$22.4B
Net debt$14.1B$10.5B$9.71B$8.48B$12.3B
Total equity$71.7B$77.9B$74.4B$75.2B$69B
Cash and short-term investments$7.66B$7.93B$8.98B$13.4B$11.2B
Income statement
20252024202320222021
Revenue$43.6B$44.3B$41.1B$40.3B$39.2B
Cost of revenue$13B$13.2B$12.6B$11.9B$12.3B
Gross profit$30.6B$31.1B$28.5B$28.4B$26.9B
Research and development expenses$7.84B$7.39B$6.51B$6.5B$5.69B
Selling, general and administrative expenses$9.54B$9.25B$9B$8.79B$9.6B
Other expenses-$-1.06B$0.00$0.00$0.00$3.51B
Operating expenses$16.3B$16.6B$15.5B$15.3B$18.8B
Cost and expenses$29.4B$29.8B$28.1B$27.2B$31B
Interest income$394M$438M$540M$173M$3M
Interest expense$563M$596M$522M$394M$362M
Depreciation and amortization$0.00$2.8B$2.96B$2.71B$2.69B
Ebitda$6.74B$11.7B$11.1B$13.1B$11.3B
Operating income$14.3B$14.5B$13B$13.1B$8.13B
Total other income/expenses, net-$-8.23B-$-7.69B-$-6.87B-$-3.16B-$-289M
Income before tax$6.02B$6.76B$6.12B$9.99B$7.84B
Income tax expense$1.04B$1.2B$1.02B$1.91B$1.56B
Net income$7.81B$5.56B$5.4B$8.37B$6.22B
Weighted average shares outstanding$1.22B$1.25B$1.25B$1.25B$1.25B
Weighted average diluted shares outstanding$1.22B$1.25B$1.26B$1.25B$1.25B
Balance sheet
20252024202320222021
Cash and short-term investments$7.66B$7.93B$8.98B$13.4B$11.2B
Net receivables$397M$10.6B$11B$10.7B$9.79B
Inventory$0.00$9.43B$9.67B$8.96B$8.72B
Total current assets$31B$42.6B$30.7B$34.1B$30.7B
Property, plant and equipment, net$11.5B$11.6B$11.8B$11.7B$12B
Goodwill and intangible assets$67.6B$66B$73.7B$71.5B$69.5B
Long-term investments$0.00$3.26B$2.67B$2.77B$2.42B
Total non-current assets$95.9B$90.2B$95.8B$92.6B$89.6B
Total assets$126.8B$132.8B$126.5B$126.7B$120.2B
Accounts payable$22.9B$7.55B$7.33B$6.81B$6.18B
Short-term debt$4.61B$4.47B$2.32B$4.45B$3.45B
Deferred revenue$0.00$0.00$0.00$269M$319M
Total current liabilities$28.3B$29.2B$24.2B$24B$21.3B
Long-term debt$17.2B$13.4B$16.1B$16.8B$19B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$26.8B$25.8B$27.9B$27.6B$29.9B
Capital lease obligations$1.47B$1.91B$2.03B$2.18B$2.11B
Total liabilities$55.1B$54.9B$52.1B$51.6B$51.2B
Common stock$0.00$2.53B$2.53B$2.52B$2.53B
Retained earnings$0.00$0.00$0.00$0.00$0.00
Accumulated other comprehensive income (loss)$0.00$70.6B$67.4B$68.2B$62.2B
Total equity$71.7B$77.9B$74.4B$75.2B$69B
Total investments$0.00$3.75B$2.94B$3.43B$3.48B
Total debt$21.8B$17.9B$18.4B$21.2B$22.4B
Net debt$14.1B$10.5B$9.71B$8.48B$12.3B
Cash flow statement
20252024202320222021
Net income$4.94B$5.5B$5.06B$8.37B$6.22B
Depreciation and amortization$5.72B$3.59B$4.43B$3.42B$3.12B
Stock-based compensation$0.00$0.00$0.00$245M$244M
Change in working capital$1.8B-$-615M$413M-$-794M$1.41B
Accounts receivable-$-1.2B-$-28M-$-472M-$-500M$185M
Inventory-$-39M-$-477M-$-866M-$-918M-$-357M
Accounts payable$398M$789M$258M$340M$451M
Net cash provided by operating activities$10.8B$9.08B$10.3B$10.5B$10.5B
Investments in property, plant and equipment-$-3.62B-$-3.24B-$-3.25B-$-2.2B-$-2.04B
Acquisitions, net$847M-$-2.52B$1.01B-$-858M-$-5.59B
Net cash used for investing activities-$-2.45B-$-4.41B-$-6.2B-$-2.08B-$-7.3B
Common stock issued$177M$187M$195M$188M$186M
Common stock repurchased-$-5.03B-$-302M-$-593M-$-497M-$-382M
Dividends paid-$-4.77B-$-4.7B-$-4.45B-$-4.17B-$-4.01B
Net cash used for financing activities-$-8.21B-$-5.76B-$-8.05B-$-5.82B-$-7.06B
Net change in cash-$-54M-$-1.27B-$-4.03B$2.64B-$-3.82B
Cash at end of period$7.39B$7.44B$8.71B$12.7B$10.1B
Operating cash flow$10.8B$9.08B$10.3B$10.5B$10.5B
Capital expenditure-$-1.76B-$-3.2B-$-1.62B-$-2.2B-$-2.04B
Free cash flow$8.99B$5.89B$8.64B$8.33B$8.48B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sanofi

        Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

        CEO
        Olivier Charmeil
        Employees
        82.88K
        Beta
        0.28

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Sanofi (SAN.PA)?

        InvestorsCraft does not currently publish an intrinsic value for SAN.PA. How the IC value is calculated.

        Is SAN.PA undervalued?

        InvestorsCraft does not publish an undervaluation signal for SAN.PA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.